Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model

Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating EGFR mutations (EGFR Mut(+)). However, almost all tumors eventually develop resistance to erlotinib. Recently, the P...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Chinami, Yanagisawa, Mieko, Yorozu, Keigo, Kurasawa, Mitsue, Furugaki, Koh, Ishikura, Nobuyuki, Iwai, Toshiki, Sugimoto, Masamichi, Yamamoto, Kaname
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504975/
https://www.ncbi.nlm.nih.gov/pubmed/28627678
http://dx.doi.org/10.3892/ijo.2017.4036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504975/
https://www.ncbi.nlm.nih.gov/pubmed/28627678
http://dx.doi.org/10.3892/ijo.2017.4036

Ejemplares similares